Table 2.
Overall survival using Cox regression.
| Characteristics | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| Hazard Ratio | 95% CI | p-Value | Hazard Ratio | 95% CI | p-Value | |
| Liver tumor histology | ||||||
| Desmoplastic | 1.00 | 1.00 | ||||
| Non-desmoplastic | 1.70 | 1.23–2.34 | 0.0010 | 1.54 | 1.09–2.15 | 0.0133 |
| Synchronous presentation | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 4.30 | 2.79–6.65 | <0.0001 | 4.13 | 2.63–6.48 | <0.0001 |
| Neoadjuvant chemotherapy before primary resection | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.87 | 1.36–2.55 | <0.0001 | 1.80 | 1.30–2.50 | 0.0004 |
| Adjuvant chemotherapy after liver resection | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.51 | 0.82–2.83 | 0.1819 | 1.54 | 0.80–2.98 | 0.1960 |
| TNM stage of primary tumor | ||||||
| 1 | 1.00 | 1.00 | ||||
| 2 | 1.67 | 0.39–7.13 | 0.4875 | 1.82 | 0.42–7.79 | 0.4208 |
| 3 | 2.96 | 0.43–12.09 | 0.1299 | 2.76 | 0.67–11.29 | 0.1588 |
| 4 | 4.98 | 1.20–20.69 | 0.0273 | 5.92 | 1.41–24.77 | 0.0149 |
| KRAS | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.43 | 0.99–2.09 | 0.0600 | 1.56 | 1.03–2.36 | 0.0373 |
| Location of primary tumor | ||||||
| Bilateral | 1.00 | 1.00 | ||||
| Right | 3.75 | 0.91–15.39 | 0.0670 | 3.32 | 0.79–14.00 | 0.1022 |
| Left | 2.26 | 0.55–9.32 | 0.2592 | 2.00 | 0.48–8.34 | 0.3442 |
| Rectum | 2.53 | 0.62–10.34 | 0.1950 | 2.13 | 0.52–8.78 | 0.2975 |
| Volume of primary tumor | ||||||
| 1.003 | 0.995–1.010 | 0.4924 | 1.002 | 0.995–1.010 | 0.5749 | |
| Greatest dimension of liver tumor | ||||||
| 0.968 | 0.912–1.028 | 0.4822 | 0.3673 | 0.907–1.029 | 0.2803 | |
| Development of extra-hepatic metastatic disease | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.82 | 1.29–2.57 | 0.0006 | 1.88 | 1.3–2.72 | 0.0007 |
| Multiple of extra-hepatic metastatic site | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.96 | 1.44–2.67 | <0.0001 | 2.02 | 1.46–2.80 | <0.0001 |
| Liver metastatic recurrence | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.46 | 1.02–2.10 | 0.0403 | 1.81 | 1.13–2.88 | 0.0127 |
| Never fully resected | 3.42 | 2.25–5.22 | <0.0001 | 1.32 | 0.79–2.22 | 0.2871 |
| Liver resection with and without BEV | ||||||
| Chemonaive | 1.00 | 1.00 | ||||
| Neoadjuvent | 2.26 | 1.42–3.59 | 0.0005 | 1.93 | 0.97–3.82 | 0.0602 |
| BEV | 1.68 | 1.02–2.76 | 0.0415 | 2.98 | 1.47–6.02 | 0.0024 |
| Number of clinically relevant mutations in liver tumors | ||||||
| 0 | 1.00 | 1.00 | ||||
| 1 | 1.76 | 1.10–2.81 | 0.0177 | 2.06 | 1.24–3.43 | 0.0053 |
| 2 | 1.20 | 0.64–2.27 | 0.5666 | 1.45 | 0.73–2.87 | 0.2912 |
| 3 | 13.42 | 1.71–105.69 | 0.0136 | 16.81 | 2.00–141.45 | 0.0094 |
| Number of clinically relevant mutations in primary tumor | ||||||
| 0 | 1.00 | 1.00 | ||||
| 1 | 1.42 | 0.80–2.52 | 0.2326 | 1.74 | 0.93–3.28 | 0.0838 |
| 2 | 1.21 | 0.55–2.64 | 0.6412 | 1.62 | 0.72–3.67 | 0.2459 |
| 3 | 39.98 | 3.56–448.71 | 0.0028 | 63.79 | 4.62–881.05 | 0.0019 |
Models are all adjusted for age at first diagnosis, gender, and BMI. Significant values are highlighted in bold.